新京报讯(记者王卡拉)11月6日,第八届进博会期间,内分泌领域创新药企维升药业与国内制药装备龙头企业东富龙科技集团(简称“东富龙”)达成双腔冻干制剂技术战略合作,并与临港新片区管委会、临港集团物贸平台签署产业协同协议,标志着其在“全球创新、中国加速”的战略实践进一步落地。 维升药业今年首次以参展商身份亮相第八届进博会,携两款全球创新药物登场亮相。其中,“全球首创”药物帕罗培特立帕肽是全球首个且...
Source Link新京报讯(记者王卡拉)11月6日,第八届进博会期间,内分泌领域创新药企维升药业与国内制药装备龙头企业东富龙科技集团(简称“东富龙”)达成双腔冻干制剂技术战略合作,并与临港新片区管委会、临港集团物贸平台签署产业协同协议,标志着其在“全球创新、中国加速”的战略实践进一步落地。 维升药业今年首次以参展商身份亮相第八届进博会,携两款全球创新药物登场亮相。其中,“全球首创”药物帕罗培特立帕肽是全球首个且...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.